Whole-Body MR Imaging: The Novel, “Intrinsically Hybrid,” Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond. Lecouvet FE et al. PET Clin. 2018 Oct. doi: 10.1016/j.cpet.2018.05.006. [Epub 2018 Aug 17] Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. Leiba M et al. Oral Dis. 2018 Oct. doi: 10.1111/odi.12901.…
The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. Jiang Yet al. Oncol Lett. 2018 Sep. doi: 10.3892/ol.2018.9128. [Epub 2018 Jul 11] Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Stolzenburg A et al. Eur J Nucl Med Mol Imaging. 2018 Sep. doi: 10.1007/s00259-018-3997-0. Determining treatment intensity…
Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Marinac CR et al. Br J Cancer. 2018 Mar 12. doi: 10.1038/s41416-018-0010-4. [Epub ahead of print]. Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: a systematic review and meta-analysis. Razi B et al. Hematology. 2018 Mar 1:1-7. doi: 10.1080/10245332.2018.1443897.…
Identification of pathway-based prognostic gene signatures in patients with multiple myeloma. Zamani-Ahmadmahmudi M et al. Transl Res. 2017 May 9. pii: S1931-5244(17)30041-5. doi: 10.1016/j.trsl.2017.05.001. [Epub ahead of print]. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Łuczak M, Kubicki T et al. Pol Arch Intern Med. 2017 May 25. doi: 10.20452/pamw.4032. [Epub ahead of…
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Chakraborty R et al. Blood Cancer J. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Botta C et al. Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma. Sasikumar A et…
Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Horger M et al. Eur Radiol. 2016 Nov 23. [Epub ahead of print]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Predictors of inferior clinical outcome in patients with…
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oliva S et al. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12641. [Epub ahead of print]. The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Sonmezoglu K et al. Nucl Med Commun. 2016 Oct 21. [Epub ahead of print]. Whole body magnetic resonance imaging in…
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Chhabra S et al. J…